Pharmaceuticals News and Research

RSS

Administration reverses course on proposed Medicare drug changes

After advancing a number of changes to the Medicare Part D program earlier this year, the Centers for Medicare & Medicaid Services withdrew its plan, which had drawn significant opposition from patients, drug companies and lawmakers in both parties.

11 Mar 2014

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

11 Mar 2014

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).

11 Mar 2014

Hi-Tech Pharmacal's third fiscal quarter net sales decrease 7% to $59.9 million

Hi-Tech Pharmacal Co., Inc. today reported results for the third fiscal quarter ended January 31, 2014.

11 Mar 2014

First Edition: March 11, 2014

Today's headlines include reports that the Centers for Medicare & Medicaid Services is stepping back from proposed changes to the Medicare drug program.

11 Mar 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: AMGN), today announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma (HCC), or liver cancer, who had no detectable disease after surgical resection or local ablation, did not meet its primary endpoint of improving recurrence-free survival.

11 Mar 2014

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Promethera Biosciences, a company that develops innovative therapies for the treatment of liver diseases, today announces a collaboration with EMD Millipore to develop an improved ready-to-use microfluidic perfusion liver assay. This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism.

11 Mar 2014

Researchers identify microbe that 'eats' electricity

There have been plenty of fad diets that captured the public's imagination over the years, but Harvard scientists have identified what may be the strangest of them all - sunlight and electricity.

11 Mar 2014

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Homologous recombination is a technology that enables the targeted insertion of nucleotide fragments into the genome of a cell. It is called ‘homologous’ because it uses a sequence that is a homologue to the sequence being targeted in a gene, so that the sequence is recognized.

10 Mar 2014

Study examines impact of the elimination of preferred pharmacy networks on Medicare Part D program

A new actuarial study released by The Pharmaceutical Care Management Association examining the impact proposed changes to the Medicare prescription drug program finds that eliminating preferred pharmacy networks in Part D would increase premiums by approximately $63 annually for over 75 percent of Part D enrollees and raise overall program costs by an estimated $24 billion over the next ten years.

10 Mar 2014

Regado receives Fast Track designation from FDA for REG1

Regado Biosciences, Inc., a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program.

10 Mar 2014

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

The American Botanical Council has presented its 2013 Varro E. Tyler Commercial Investment in Phytomedicinal Research Award to Wakunaga Pharmaceutical Company, Ltd., of Osaka, Japan. Since its founding in 1955, the company has been committed to rigorous scientific and clinical research of its products, including its top-selling, clinically researched odorless Aged Garlic Extract¨.

10 Mar 2014

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

BerGenBio AS, an oncology biopharmaceutical company, is pleased to announce the award of a NOK 13 million grant from the Research Council of Norway's User-driven Research based Innovation programme (BIA) to help fund research into novel therapeutics for inhibiting tumor epithelial-mesenchymal transition (EMT), a key driver of metastasis (cancer spread) and a mechanism of drug-resistance.

10 Mar 2014

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Illumina, Inc. and WuXi PharmaTech (Cayman) Inc., a leading pharmaceutical, biotechnology, and medical device R&D outsourcing company with operations in China and the United States, today announced that the WuXi Genome Center has purchased an Illumina HiSeq X Ten sequencing system.

From Illumina, Inc. 10 Mar 2014

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Fibrotech, an Australian biopharmaceutical company developing a new class of drugs to prevent a massive health burden associated with fibrosis, today announced that its lead anti-fibrotic compound FT011 has successfully completed a Phase Ia trial in healthy volunteers demonstrating safety and tolerability up to doses of 1000mg.

10 Mar 2014

Proteus Digital Health teams up with leading organisations to bring digital health technology to the UK

Leading digital medicines company Proteus Digital Health is partnering with Eastern Academic Health Science Network, The Northern Health Science Alliance and Oxford University, Oxford University Hospitals NHS Trust and Oxford Academic Health Science Network to bring digital health technology and global operations and manufacturing to the UK.

10 Mar 2014

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the back of the eye, today announces that it has been awarded a €3 million grant from the Flemish agency for Innovation by Science and Technology.

10 Mar 2014

Pharmaceuticals News and Research

Administration reverses course on proposed Medicare drug changes

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Hi-Tech Pharmacal's third fiscal quarter net sales decrease 7% to $59.9 million

First Edition: March 11, 2014

Bayer and Onyx announce Phase 3 trial evaluating use of NEXAVAR for patients with HCC after local ablation

Promethera Biosciences, EMD Millipore partner to develop ready-to-use microfluidic perfusion liver assay

Researchers identify microbe that 'eats' electricity

Homologous recombination technology for research applications in genetically modified rodents: an interview with Alexandre Fraichard, CEO, genOway

Study examines impact of the elimination of preferred pharmacy networks on Medicare Part D program

Regado receives Fast Track designation from FDA for REG1

ABC Varro E. Tyler Commercial Investment in Phytomedicinal Research Award presented to Wakunaga

BerGenBio receives grant to study novel therapeutics for inhibiting epithelial-mesenchymal transition

WuXi Genome Center buys Illumina HiSeq X Ten sequencing system

Fibrotech successfully completes Phase Ia trial of anti-fibrotic compound FT011

Proteus Digital Health teams up with leading organisations to bring digital health technology to the UK

ThromboGenics receives IWT grant to study potential new biotherapeutics for DME

Takeda works with UCL to drive research into tackling muscle disorders

Edison Pharmaceuticals initiates Phase 2B/3 study of EPI-743 in children with Leigh syndrome

Aptel Research releases newest report Patient Voices Series Rheumatoid Arthritis

Event guide: World ADC Asia eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring